BORJE S ANDERSSON to Time Factors
This is a "connection" page, showing publications BORJE S ANDERSSON has written about Time Factors.
Connection Strength
0.256
-
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
Score: 0.061
-
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64.
Score: 0.022
-
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2003 Oct; 5(5):679-91.
Score: 0.021
-
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
Score: 0.017
-
The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996 Jul; 28(1):162-7.
Score: 0.013
-
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
Score: 0.013
-
Human isolates of Listeria monocytogenes in Sweden during half a century (1958-2010). Epidemiol Infect. 2014 Nov; 142(11):2251-60.
Score: 0.011
-
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41.
Score: 0.010
-
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
Score: 0.009
-
Life table analysis for estimation of duration of aplasia after high-dose chemotherapy. Eur J Haematol. 1990 Nov; 45(5):284-5.
Score: 0.009
-
Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Apr; 45(4):647-55.
Score: 0.008
-
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.
Score: 0.008
-
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May; 41(9):771-8.
Score: 0.007
-
Mitochondrial transmembrane potential and pH gradient during anoxia. Am J Physiol. 1987 Apr; 252(4 Pt 1):C349-55.
Score: 0.007
-
Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006 Feb; 253(2):163-70.
Score: 0.006
-
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
Score: 0.006
-
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9.
Score: 0.005
-
Post mortem, ultrastructural cardiac muscle changes and anthracycline toxicity. Biomed Pharmacother. 1983; 37(6):281-7.
Score: 0.005
-
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
Score: 0.003
-
Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1073-9.
Score: 0.003
-
Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol. 1995 Dec; 91(4):838-45.
Score: 0.003
-
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 1993 Jan; 11(1):55-9.
Score: 0.003
-
Suppression of mitochondrial respiratory function after short-term anoxia. Am J Physiol. 1987 Apr; 252(4 Pt 1):C362-8.
Score: 0.002
-
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
Score: 0.002
-
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Cancer Chemother Pharmacol. 1981; 5(4):261-6.
Score: 0.001
-
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):19-24.
Score: 0.001